SEC EDGAR 8-KNov 9$NOTE

FiscalNote Reports Third Quarter 2026 Financial Results

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FiscalNote Reports Third Quarter 2026 Financial Results Adjusted EBITDA Rises to $3.6 Million on Lower Costs; Reaffirms FY26 Guidance and Establishes Q4 2026 Forecast WASHINGTON, D. C. – November 9, 2026 – FiscalNote Holdings, Inc. (OTCID: NOTE) (“FiscalNote” or the

Original reporting

SEC EDGAR 8-K

Published Nov 9, 2026, 9:30 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 9:35 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefEarnings

Primary signal

$NOTE

Neutral

high confidence

Mentioned

$NOTE

Relevance

7/10

AlphAI data visualization · based on SEC EDGAR 8-K

Decision brief

The 30-second read

$NOTENeutralLow

Why it matters

The reaffirmed FY26 guidance suggests stability but limited upside; the market may react modestly.

Market read

The filing offers fresh earnings data for a micro‑cap SaaS firm, with limited broader market relevance.

What to watch

The divestiture of FrontierView reduces debt and may improve margins over the longer term.

Relevance 7/10Novelty 6/10Timing: post‑market release

Background

FiscalNote Holdings, a provider of AI‑driven policy and regulatory intelligence, filed its quarterly 8‑K with detailed financials and operational updates.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NOTENeutralHigh confidence

Context

FiscalNote Holdings reported Q3 2026 results, reaffirmed FY26 guidance and provided a Q4 forecast in its 8‑K filing.

Expected impact

likely modest pressure as the market prices in the reaffirmed outlook and lower loss profile

Evidence & confidence

The filing contains fresh numbers but no surprise upside; investors may view the reaffirmation as status‑quo, limiting upside potential.

Market effects

Sector

Provides a data point for the policy‑intelligence SaaS niche, but unlikely to shift sector sentiment.

Regional

Limited to U.S. investors tracking micro‑cap tech stocks.

Global

Minimal global impact; the company is a niche player.

Counterpoint

What could challenge this read

If investors expect a turnaround, the reaffirmed guidance could be seen as a catalyst for a bounce.

Key entities

Executive
Key Compton
CEO and President of FiscalNote, quoted on the quarterly results.

Read at source ← All news

$NOTEMed

FiscalNote Holdings, Inc. (NOTE): Completion of Acquisition or Disposition of Assets

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 FiscalNote Announces and Completes the Sale of FrontierView to Oxford Economics, Sharpening Focus on Core Policy Business Transaction Further Simplifies the Core Business, Drives Operating Efficiencies, and Strengthens the Balance Sheet FiscalNote Updates Full-Year 2

SEC EDGAR 8-KSep 2

$NOTEMed

FiscalNote Reports Second Quarter 2026 Financial Results

FiscalNote Holdings, Inc. (NOTE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FiscalNote Reports Second Quarter 2026 Financial Results Total Revenue In Line with Guidance; Adjusted EBITDA Slightly Below Guidance; Establishes Q3 2026 Forecast and Revises FY26 Guidance Company To Host Conference Call Today at 5:00 PM ET WASHINGTON, D. C. – Augus

SEC EDGAR 8-KAug 10

$OVIDMed

Ovid Therapeutics Reports Q3 Results; Multiple Pipeline Readouts Expected In 2027

Ovid Therapeutics (OVID) reported Q3 2026 results, with R&D expenses rising to $15.7M and net loss widening to $20.8M. The company expects 2027 milestones for OV329 and OV4071, including Phase 1 and 2 data. Cash reserves total $161.4M, expected to last into 2029. OVID is down 0.70% at $2.83.

rttnews.comNov 10

$ASTSHigh

AST SpaceMobile Wants 45 Satellites in Orbit by Mid-2027 After Revenue Nearly Tripled

AST SpaceMobile (ASTS) reported Q3 2026 revenue of $42.3M, up 187% YoY. The company expects 45 satellites in orbit by mid-2027, delayed from prior targets. Shares rose 14.1% on Nov 9, 2026, before slipping after hours. ASTS reaffirmed 2026 revenue guidance of $150M-$200M, with Q4 relying on milestone payments. The company has $3.2B in cash reserves.

247wallst.comNov 10

$LINEHighAI 8/10

What Lineage (LINE) Said on Its Q3 Earnings Call

Lineage (LINE) revised its full-year same-store NOI forecast to a 3% to 2% decline, citing international trade pressures and reduced container volumes. GIS segment NOI fell 13.8% in Q3, with margins squeezed by rising carrier costs. The company expects margin recovery in coming quarters and plans to use asset sale proceeds to reduce leverage and fund development.

finance.yahoo.comNov 10

$LEGNMed

What Legend Biotech (LEGN) Said on Its Q3 Earnings Call

Legend Biotech (LEGN) reported a 32% year-over-year revenue increase, with adjusted net income of $55.6M. CEO Ingrid Zhang expects CARVYKTI to generate over $5B in peak sales. The company improved gross margins and reduced R&D expenses. Legend also received FDA clearance for a clinical study of LB2501 and shared positive interim data. The company remains debt-free with $853M in cash equivalents.